ArticleGalen medical journal2025
Myrtle Syrup Improves Proteinuria in Type 2 Diabetic Patients: A Randomized Double-blinded Placebo-controlled Clinical Trial : Myrtle Syrup Improves Proteinuria in Type 2 Diabetes.
Article in Galen medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The use of medicinal plants as an alternative to synthetic drugs is increasing due to their accessibility and safety. In Iranian traditional medicine, myrtle (Myrtus communis) is widely recommended for treating kidney diseases, but scientific evidence supporting this claim is lacking. This study aimed to investigate the therapeutic effect of myrtle syrup (M. syrup) on proteinuria in patients with type 2 diabetes. Materials and Methods: This randomized, double-blind, placebo-controlled trial included 62 subjects aged 18-75 years with type 2 diabetes. Participants were randomly assigned to receive either M. syrup (10 cc) twice daily or a placebo syrup for 24 days. Enzyme-based commercial kits were used to measure serum levels of hemoglobin A1c (HbA1c), fasting blood sugar (FBS), blood urea nitrogen (BUN), creatinine, and protein in both serum and urine. 24-hour urine volume was also measured. Data analysis was performed using likelihood ratio chi-square tests, with statistical significance set at P0.05. Results: The results showed that M. syrup significantly improved proteinuria compared with the placebo group (P0.001). The mean change in urine protein was a decrease of 129 units in the intervention group and an increase of 16.5 units in the placebo group. However, no significant effects were observed on FBS, HbA1c, BUN, urine volume, serum creatinine, and urine creatinine. The potential mechanism of action for M. syrup in reducing proteinuria may be attributed to its antioxidant and anti-inflammatory properties. Conclusion: M. syrup supplementation may be an effective adjunct therapy for proteinuria in patients with type 2 diabetes. Hence, this should be emphasized in this regard.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.